Bromodomain-containing proteins in prostate cancer

Alfonso Urbanucci, Ian G Mills

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates a ligand-binding domain, which has become a drug target for competitive inhibitors, other transcription factors often do not have tractable binding pockets that aid drug development. Consequently drug development efforts have turned to transcription co-regulators, often chromatin-modifying enzymes or factors that bind to epigenetic modifications to chromatin. Bromodomain (BRD)-containing proteins fall into the latter category and significant progress has been made in developing small molecule inhibitors that target a particular subgroup of BRD-containing proteins known as the Bromodomain and extra-terminal (BET) family proteins. These inhibitors have proven particularly effective in inactivating c-Myc in lymphoma but more recently members of the BET family have also been identified as AR-interacting proteins raising the prospect of using these inhibitors as an alternative strategy for targeting AR-driven cancers. In this review we will provide an overview of BRD-containing proteins and the potential for exploiting them as biomarkers and drug targets in prostate cancer.

Original languageEnglish
JournalMolecular and Cellular Endocrinology
Volume462
Issue numberPart A
Early online date14 Jun 2017
DOIs
Publication statusPublished - 15 Feb 2018

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Pharmaceutical Preparations
Chromatin
Proteins
Receptor-Interacting Protein Serine-Threonine Kinases
Biomarkers
Transcription
Epigenomics
Lymphoma
Transcription Factors
Ligands
Molecules
Enzymes
Neoplasms
Therapeutics

Keywords

  • Journal Article
  • Review

Cite this

@article{5e09c46d34b14f83bcf3735393124fb0,
title = "Bromodomain-containing proteins in prostate cancer",
abstract = "Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates a ligand-binding domain, which has become a drug target for competitive inhibitors, other transcription factors often do not have tractable binding pockets that aid drug development. Consequently drug development efforts have turned to transcription co-regulators, often chromatin-modifying enzymes or factors that bind to epigenetic modifications to chromatin. Bromodomain (BRD)-containing proteins fall into the latter category and significant progress has been made in developing small molecule inhibitors that target a particular subgroup of BRD-containing proteins known as the Bromodomain and extra-terminal (BET) family proteins. These inhibitors have proven particularly effective in inactivating c-Myc in lymphoma but more recently members of the BET family have also been identified as AR-interacting proteins raising the prospect of using these inhibitors as an alternative strategy for targeting AR-driven cancers. In this review we will provide an overview of BRD-containing proteins and the potential for exploiting them as biomarkers and drug targets in prostate cancer.",
keywords = "Journal Article, Review",
author = "Alfonso Urbanucci and Mills, {Ian G}",
note = "Copyright {\circledC} 2017. Published by Elsevier B.V.",
year = "2018",
month = "2",
day = "15",
doi = "10.1016/j.mce.2017.06.007",
language = "English",
volume = "462",
journal = "Molecular and Cellular Endocrinology",
issn = "0303-7207",
publisher = "Elsevier Ireland Ltd",
number = "Part A",

}

Bromodomain-containing proteins in prostate cancer. / Urbanucci, Alfonso; Mills, Ian G.

In: Molecular and Cellular Endocrinology, Vol. 462, No. Part A, 15.02.2018.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Bromodomain-containing proteins in prostate cancer

AU - Urbanucci, Alfonso

AU - Mills, Ian G

N1 - Copyright © 2017. Published by Elsevier B.V.

PY - 2018/2/15

Y1 - 2018/2/15

N2 - Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates a ligand-binding domain, which has become a drug target for competitive inhibitors, other transcription factors often do not have tractable binding pockets that aid drug development. Consequently drug development efforts have turned to transcription co-regulators, often chromatin-modifying enzymes or factors that bind to epigenetic modifications to chromatin. Bromodomain (BRD)-containing proteins fall into the latter category and significant progress has been made in developing small molecule inhibitors that target a particular subgroup of BRD-containing proteins known as the Bromodomain and extra-terminal (BET) family proteins. These inhibitors have proven particularly effective in inactivating c-Myc in lymphoma but more recently members of the BET family have also been identified as AR-interacting proteins raising the prospect of using these inhibitors as an alternative strategy for targeting AR-driven cancers. In this review we will provide an overview of BRD-containing proteins and the potential for exploiting them as biomarkers and drug targets in prostate cancer.

AB - Several oncogenic factors have been involved in prostate cancer progression. However, therapeutic approaches still focus on suppression of androgen receptor (AR) signaling. In fact, whereas the full-length AR incorporates a ligand-binding domain, which has become a drug target for competitive inhibitors, other transcription factors often do not have tractable binding pockets that aid drug development. Consequently drug development efforts have turned to transcription co-regulators, often chromatin-modifying enzymes or factors that bind to epigenetic modifications to chromatin. Bromodomain (BRD)-containing proteins fall into the latter category and significant progress has been made in developing small molecule inhibitors that target a particular subgroup of BRD-containing proteins known as the Bromodomain and extra-terminal (BET) family proteins. These inhibitors have proven particularly effective in inactivating c-Myc in lymphoma but more recently members of the BET family have also been identified as AR-interacting proteins raising the prospect of using these inhibitors as an alternative strategy for targeting AR-driven cancers. In this review we will provide an overview of BRD-containing proteins and the potential for exploiting them as biomarkers and drug targets in prostate cancer.

KW - Journal Article

KW - Review

U2 - 10.1016/j.mce.2017.06.007

DO - 10.1016/j.mce.2017.06.007

M3 - Review article

C2 - 28624514

VL - 462

JO - Molecular and Cellular Endocrinology

JF - Molecular and Cellular Endocrinology

SN - 0303-7207

IS - Part A

ER -